Catalyst Pharmaceutical Seen Posting 40% EPS Drop and $140M Q4 Revenues
Catalyst Pharmaceutical is projected to post EPS of $0.42 for Q4 2025, a 40% year-over-year decline, on revenues of $140.02 million, down 1.3%. Its Earnings ESP of -47.93% and unchanged consensus EPS estimate contrast with a Zacks Rank #3, signaling low odds of a positive surprise.
1. Estimated Q4 Results
Catalyst Pharmaceutical is expected to report EPS of $0.42 for the quarter ended December 2025, down 40% from $0.70 a year earlier. Revenue is forecast at $140.02 million, a 1.3% decline, with the report due on February 25.
2. Earnings ESP and Consensus
The Most Accurate Estimate lies below the consensus EPS, generating an Earnings ESP of -47.93%, reflecting analysts’ recent downward revisions. The consensus EPS and revenue estimates have remained unchanged over the last 30 days.
3. Zacks Rank and Surprise History
Catalyst carries a Zacks Rank #3 (Hold), which dampens the predictive power of a negative ESP for an upside surprise. The company has delivered four consecutive EPS beats, but this quarter’s deep negative ESP suggests potential headwinds.